Étiquette : pharmacologie

Bibliographie : MDMA – Ecstasy, Docteur Christian Sueur, GRECC, mars 2023

Bibliographie MDMA - Ecstasy   Docteur Christian Sueur, GRECC, mars 2023   MDMA : généralités, sociologie…, pp 1 - 3. MDMA : pharmacologie, pp 4 - 9. MDMA : neurophysiologie, pp 10 - 15. MDMA : toxicologie, pp 16 - 22. MDMA : analyses pharmacologiques, « réduction des risques », pp 23 - 24. MDMA : psychopathologie, pp 25 - 26. MDMA : enthéogénie, p 27. MDMA : thérapeutique, pp 28 - 34.

Lire la suite

Mort du chercheur Raphael Mechoulam, chantre du chanvre médical, Libération, 13 mars 2023

Mort du chercheur Raphael Mechoulam, chantre du chanvre médical par Charles Delouche-Bertolasi Libération,13 mars 2023 Pionnier de l’utilisation médicale du cannabis, le scientifique israélien est mort le 9 mars à Jérusalem, à l’âge de 92 ans. Entre autres découvertes, il est celui qui a réussi en 1964 à isoler le THC, principe actif du cannabis. Raphael Mechoulam, lors d'une conférence à Tel Aviv, en mars 2016. (JACK GUEZ/AFP) Depuis quelques jours, certains fumeurs de joints dédient leurs exhalaisons à un homme, qui vient de s’éteindre en Israël à l’âge de 92 ans : le docteur Raphael Mechoulam, chimiste et scientifique, chercheur pionnier à l’origine de la découverte du delta-9 [...]

Lire la suite

Raphael Mechoulam, « père de la recherche sur le cannabis », est décédé à l’âge de 92 ans, Aurelien Bernard, Newsweed, 2023

Raphael Mechoulam, « père de la recherche sur le cannabis », est décédé à l’âge de 92 ans Aurélien BERNARD Newsweed.org, 10 mars 2023 Le célèbre scientifique spécialiste du cannabis Raphael Mechoulam est décédé à l’âge de 92 ans. La nouvelle a été annoncée par des amis et des collègues qui ont fait part de leurs condoléances et de leurs hommages. « C’est un jour très triste pour moi, pour la communauté scientifique et pour la communauté du cannabis. Le professeur Raphael Mechoulam, que nous appelions Raphi, était l’un des plus grands scientifiques que j’aie jamais rencontrés, mon professeur et mon mentor à bien des égards. Je crois [...]

Lire la suite

Assessing the treatment of cannabidiolic acid methyl ester: a stable synthetic analogue of cannabidiolic acid on c‑Fos and NeuN expression in the hypothalamus of rats Eric Murillo‑Rodríguez, Roger G. Pertwee, Raphael Mechoulam et al., 2021

Assessing the treatment of cannabidiolic acid methyl ester: a stable synthetic analogue of cannabidiolic acid on c‑Fos and NeuN expression in the hypothalamus of rats Eric Murillo‑Rodríguez, Diana Millán‑Aldaco, Gloria Arankowsky‑Sandoval, Tetsuya Yamamoto, Roger G. Pertwee, Linda Parker and Raphael Mechoulam     Abstract Background : Cannabidiol (CBD), the non-psychotropic compound from Cannabis sativa, shows positive results on controlling several health disturbances; however, comparable data regarding additional chemical from C. sativa, such as cannabidiolic acid (CBDA), is scarce due to its instability. To address this limitation, a stable CBDA analogue, CBDA methyl ester (HU-580), was synthetized and showed CBDA-like effects. Recently, we described that HU-580 increased [...]

Lire la suite

Psychedelic psychiatry’s brave new world, Nutt, D., Erritzoe, D., & Carhart-Harris, R., 2020

Psychedelic psychiatry’s brave new world. Nutt, D., Erritzoe, D., & Carhart-Harris, R. Cell, 2020, 181, (1), 24-28. Doi : 10.1016/j.cell.2020.03.020   After a legally mandated, decades-long global arrest of research on psychedelic drugs, investiga- tion of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction.   Introduction—Why the Psychedelic Revolution in Psychiatry? Research leading to the discovery of new pharmacological treatments for psychiat- ric disorders has been painfully slow. With a few exceptions, including the use of orexin [...]

Lire la suite

The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances : Origins, Samuel D. Banister and Mark Connor, 2018

The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances : Origins Samuel D. Banister and Mark Connor Handbook of Experimental Pharmacology, # Springer International Publishing AG, part of Springer Nature 2018 doi : 10.1007/164_2018_143   Contents 1 Introduction 2 Chemical Classification of Synthetic Cannabinoid Receptor Agonists 3 Cannabinoid Type 1 Receptor (CB1) Structure and Function 4 Historical Synthetic Cannabinoid Receptor Agonists 4.1 Classical Cannabinoids and Phytocannabinoid Analogs 4.2 Nonclassical Cannabinoids 4.3 Aminoalkylindoles (AAIs) 5 Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances 5.1 Molecular Hybridization 5.2 Bioisosteric Fluorination 6 Conclusions References Abstract Synthetic cannabinoid receptor agonists (SCRAs) have proliferated as new psychoactive substances (NPS) over the past decade. Relative to other classes of NPS, SCRAs [...]

Lire la suite

Cannabinoids and Neurogenesis : The Promised Solution for Neurodegeneration ?, Andrea Valeri and Emanuela Mazzon, 2021

Cannabinoids and Neurogenesis : The Promised Solution for Neurodegeneration ? Andrea Valeri and Emanuela Mazzon Molecules, 2021, 26, 6313, 1-26. doi : 10.3390/molecules26206313   Abstract : The concept of neurons as irreplaceable cells does not hold true today. Experiments and evidence of neurogenesis, also, in the adult brain give hope that some compounds or drugs can enhance this process, helping to reverse the outcomes of diseases or traumas that once were thought to be everlasting. Cannabinoids, both from natural and artificial origins, already proved to have several beneficial effects (e.g., anti-inflammatory, anti-oxidants and analgesic action), but also capacity to increase neuronal population, by replacing the [...]

Lire la suite

Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications, Arianna Giorgetti et al., 2021

Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications Arianna Giorgetti, Jennifer P. Pascali, Paolo Fais, Guido Pelletti, Andrea Gabbin, Giorgia Franchetti, Giovanni Cecchetto  and Guido Viel Life, 2021, 11, 440, 1-17. doi : 10.3390/life11050440   Abstract : Novel psychoactive substances (NPS) represent a severe health risk for drug users. Even though the phenomenon has been growing since the early 2000s, the mechanisms of action of NPS at the receptors and beyond them are still scarcely understood. The aim of the present study was to provide a systematic review of the updated knowledge regarding the molecular [...]

Lire la suite

Bibliographie : Cannabis et Cannabinoides en Psychiatrie, Docteur Christian Sueur, GRECC, janvier 2022

Bibliographie : Cannabis et Cannabinoides en Psychiatrie   Docteur Christian Sueur, GRECC, janvier 2022. (5e version, janvier 2022....)   1 - Généralités : 1 - 11 2 -Cannabinoïdes et anxiété : 12 3 - Cannabidiol anxiolytique : 13 - 15 4 - Cannabidiol antipsychotique : 16 - 21 5 - Cannabinoïdes et dépression : 22 - 28 6 - Cannabidiol antidépresseur : 28 7 - Cannabinoïdes et Sommeil : 29 - 30 8 - Cannabinoïdes et addiction / Substance Use Disorders : 31 - 33 9 - Cannabinoïdes et addiction au Cannabis : 34 - 43 10 - Cannabinoïdes et addictions (cocaine, opiacés, amphétamines, alcool, tabac) : 44 - 57 11 - Cannabinoides et syndrome de Gilles [...]

Lire la suite

The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders : Molecular Mechanisms and Targets, Rosa Maria Vitale et al., 2021

The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets Rosa Maria Vitale, Fabio Arturo Iannotti and Pietro Amodeo International journal of Molecular Sciences, 2021, 22, 4876, 1-20. Doi : 10.3390/ijms22094876   Abstract : Cannabidiol (CBD), the major nonpsychoactive Cannabis constituent, has been proposed for the treatment of a wide panel of neurological and neuropsychiatric disorders, including anxiety, schizophrenia, epilepsy and drug addiction due to the ability of its versatile scaffold to interact with diverse molecular targets that are not restricted to the endocannabinoid system. Albeit the molecular mechanisms responsible for the therapeutic effects of CBD have yet to be fully elucidated, many [...]

Lire la suite